_{A message from our friends at The Oxford Club (sponsor)}

Oil Just Crossed $100. Here's How I'm Playing It.

Dear Reader,

Oil just crossed $100 a barrel for the first time since 2022.

The Middle East is on fire. The Strait of Hormuz is under siege. And American energy is more valuable than it's been in years.

Which brings me to something very important... what I consider to be the perfect place to park $1,000 right now.

I'm talking about a single account - backstopped entirely by 880,000 acres of American oil and gas - that has surged 81% since early February.

But here's the thing...

This is just the beginning.

This American oil and gas account has been one of the greatest investments in American history.

It's been compounding wealth since 1888!

Through World War I. World War II. Korea. Vietnam. The dot-com crash. The Great Recession. COVID.

No matter what chaos hit the markets... it kept compounding fortunes.

Click this link to see how $1,000 parked here in 2000 would be worth over $556,000 today.

That's an average return of 29% per year for 25 straight years.

Which is why I call it "The 29% Account."

But with oil where it is right now... and no end in sight...

I might have to start calling it "The 129% Account."

I'll show you exactly what it is and how to get started.

Click here to see my "eye-opening" research for yourself.

Good investing,

Marc Lichtenfeld
Chief Income Strategist, The Oxford Club

P.S. This isn't speculation. It's 137 years of proof.

Watch my full presentation here.

The Active Trader Daily protocol you attached calls for a numbers-first, catalyst-driven editorial with institutional tone, sector context, technical framing, and bull/base/bear scenario work. It also explicitly emphasizes revenue figures, growth rates, valuation multiples, catalyst timelines, and trader-focused interpretation over generic commentary.

That framework fits Lilly perfectly right now because today’s drop looks dramatic on the chart, but the real story is not a broken company. It is a stock that had been priced as if execution would remain almost frictionless in obesity, diabetes, and the coming oral GLP-1 market. Once a stock reaches a valuation like Lilly’s, small changes in narrative matter more than large changes in fundamentals.

That is the key distinction traders need to make.

Lilly is not falling because demand disappeared. Reuters’ February coverage made the opposite point: the company guided to roughly 25% revenue growth in 2026, sees sales well above prior Street expectations, and continues to benefit from surging demand for Zepbound and Mounjaro.

The problem is that the market is now moving from “Lilly owns the obesity category” to “Lilly still leads, but the category is getting more crowded, more price-sensitive, and more dependent on flawless execution.” That is a very different multiple conversation.

The obesity-drug complex is also no longer a simple two-player story. Novo Nordisk remains the most obvious rival, but Reuters has highlighted an increasingly crowded field that includes Roche, Structure Therapeutics, and other oral-obesity developers. The strategic question has shifted from who has the best injectable today to who can win the much broader oral market over the next several years.

That is why a 6% down day in Lilly should be read less like a one-off headline reaction and more like a repricing of expectations across three variables at once: pricing, competition, and timeline risk.

The underlying business still looks formidable.

Lilly reported Q4 2025 revenue of $19.3 billion, versus analyst expectations of $17.96 billion, while adjusted EPS came in at $7.54 versus consensus near $6.67. Reuters reported the company expects 2026 sales of $80 billion-$83 billion, also ahead of Wall Street’s prior estimate of $77.62 billion, with adjusted EPS of $33.50-$35.00.

Those are not the numbers of a business in trouble.

The obesity and diabetes franchise remains the engine. Reuters reported Q4 Mounjaro sales of $7.41 billion and Q4 Zepbound sales of $4.3 billion, both ahead of analyst expectations. Zepbound’s U.S. demand was driven by volume, while international Mounjaro growth was also primarily volume-led.

But this is exactly where the valuation issue comes in.

A company growing this quickly can still see its stock fall sharply if the market decides that peak assumptions were too easy. Lilly’s CFO told Reuters that price would be a drag on percentage growth in the low- to mid-teens, driven by the government access agreement for obesity medicines, updated direct-to-patient pricing, and lower Medicaid pricing for later-life-cycle products.

That matters because Lilly’s stock has been priced not just on volume growth, but on the assumption that it could largely preserve premium economics while expanding access. The market is now testing that assumption harder.

There is also the orforglipron layer.

On the bullish side, Reuters reported Lilly is preparing to launch the drug in the U.S. as early as Q2 2026, has already built $1.5 billion in pre-launch inventory, and believes it can begin shipping within a week of approval. That is aggressive commercial readiness.

On the less comfortable side, Reuters also reported full data showed orforglipron had higher rates of side effects and discontinuations than Novo’s oral semaglutide in a head-to-head diabetes study. About 58% of patients on a 36 mg dose of Lilly’s drug reported mild-to-moderate side effects versus 45% on 14 mg Rybelsus, while about 10% discontinued Lilly’s drug versus 5% for Rybelsus. Lilly’s defense is that patients got better glycemic control and greater weight loss, but the tolerability question remains live.

So the financial model is still powerful. The question is how much of that power was already capitalized into the stock price before today.

At roughly $930.35, Lilly still trades with a market cap near $685.8 billion and a trailing P/E around 37.2x. That is not a panic valuation. That is a premium healthcare growth multiple being slightly marked down.

The most useful way to understand today’s move is this:

Lilly is no longer being judged only on whether Zepbound and Mounjaro are selling well. They clearly are.

It is being judged on whether it can remain the central owner of the next obesity category as the market evolves from injectable scarcity to oral abundance.

That is a different strategic problem.

Owning a constrained injectable market with extraordinary demand is one thing. Owning a future oral market with more competitors, more manufacturing capacity, more payer scrutiny, and more price transparency is another. Reuters reported Novo already launched a Wegovy pill in the U.S. in January, while Lilly’s own oral launch is expected in the second quarter if approved. That means the market is beginning to compare platform depth, not just current sales leadership.

This is where Structure Therapeutics becomes relevant to Lilly’s stock even though it is much smaller.

Reuters reported Structure’s aleniglipron showed up to 16.3% weight loss in a mid-stage study, and at least three analysts said it showed potential best-in-class efficacy among oral drugs, versus around 12% associated with Lilly’s oral profile. That does not mean Structure suddenly overtakes Lilly. It does mean investors now have another proof point that the oral market may become more competitive than the market previously assumed.

So Lilly is not being sold like a failed drug story.

It is being sold like a dominant company whose future category might be more contested and less lucrative than the most aggressive bulls assumed.

Lilly’s selloff matters beyond Lilly because it affects how traders should read the entire obesity-drug complex.

First, it reinforces that this market is evolving from a shortage narrative to a competition narrative. In the shortage phase, leaders with capacity win. In the competition phase, leaders still win, but the market begins to focus much more on pricing, tolerability, adherence, payer access, and the convenience of oral delivery.

Second, it widens the set of relevant comparables. Investors now have to watch not only Novo Nordisk, but also Roche, Structure Therapeutics, and any company with a credible oral-obesity pathway. Reuters reported Roche’s obesity candidate showed 22.5% weight loss in a Phase II trial in January, though investor reaction was more measured because the space is now so competitive.

Third, it raises the importance of regulatory and commercial execution. Lilly’s oral launch timing matters more now because the market wants to know whether it can turn its manufacturing scale and commercial force into early oral share before the field broadens further. Reuters’ March 2 piece made clear Lilly is preparing for immediate rollout, which suggests management understands the window matters.

Fourth, the pressure is not just about rival drugs. Reuters also highlighted Lilly’s fight against compounded tirzepatide and its concerns over impurities in compounded products. That is partly a safety issue and partly a market-structure issue. Any channel that weakens the pricing umbrella for branded obesity treatments matters to the stock.

From a trading perspective, this was not a mild dip.

LLY opened around $979.00, traded as high as $984.94, and then sold down to $925.43 before settling near $930.35. That is a large intraday breakdown in a mega-cap healthcare name. It tells you institutional selling was real, not just retail noise.

The first technical issue is gap failure.

The stock did not just drift lower. It failed early, lost the open, and then extended lower into the session. That usually indicates active distribution rather than simple profit-taking. Under the ATD framework, that is the kind of session traders should read as a momentum-reset event, not a routine red day.

The second issue is support.

The low around $925.43 now becomes an obvious short-term line. If the stock stabilizes above that zone and starts reclaiming lost ground, traders can argue today was a violent but tradable repricing. If it loses that level quickly, the next market message is that the selloff was not enough to fully clear positioning.

The third issue is VWAP and recovery quality in the next one to three sessions.

For a stock like Lilly, strong names usually show one of two reactions after a flush: either an immediate reclaim driven by institutional dip-buying, or a quiet stabilization with narrowing intraday ranges. What traders should not want to see, if they are constructive, is repeated failed rebounds into the high $940s or $950s.

The fourth issue is relative strength versus peers.

Novo was only modestly lower on the day at about $38.43, while Vertex was down less than 1%. If Lilly continues to underperform even as healthcare peers remain relatively stable, that suggests the market is targeting Lilly-specific expectations rather than just de-risking pharma broadly.

The bull case is that today’s move was a premium-multiple reset, not the start of a lasting breakdown.

For that to hold, traders would need to see Lilly stabilize above the $925 area, regain part of the drop, and shift focus back toward the company’s still-exceptional fundamentals: $19.3 billion in Q4 revenue, $80 billion-$83 billion 2026 sales guidance, and the likely Q2 launch of orforglipron. The bull argument is that even if the oral market gets more competitive, Lilly still has the biggest commercial machine and the strongest current obesity franchise.

The base case is that Lilly enters a digestion phase.

That would mean the stock stops collapsing, but does not immediately snap back, because investors now want more evidence on three fronts: the FDA timeline for orforglipron, the commercial reception of Lilly’s oral entry, and how much pricing pressure the franchise can absorb while still producing elite growth. This is probably the most realistic short-term path because the business remains strong, but today’s selloff shows expectations had become rich.

The bear case is that the market has only begun to compress Lilly’s multiple.

That would likely require some combination of softer sentiment around oral obesity competition, a more cautious view on tolerability, additional analyst downgrades, or any sign that pricing pressure is worsening faster than volume can offset it. If the stock breaks decisively below the day’s low, the market may start reframing Lilly less as an unstoppable category leader and more as a great company whose best-margin years are being challenged by competition and access expansion.

For traders, the next move in Lilly should be approached through confirmation, not conviction.

Watch three things.

First, watch whether $925-$930 holds. That is now the clearest near-term technical line on the board. A hold suggests the market may have found an initial clearing level. A break suggests the repricing is still active.

Second, watch the oral-obesity newsflow. Lilly’s near-term stock narrative is increasingly tied to orforglipron’s approval timing, launch readiness, side-effect profile, and how it stacks up against newer oral entrants. Reuters’ March coverage makes clear this is no longer a background issue. It is central to the valuation debate.

Third, watch analyst tone and sector relative performance. A same-day downgrade can intensify selling in a premium stock, but the more important question is whether the broader analyst community starts cutting targets materially or simply treats today as a reset. Today’s flow looks like a confidence shakeout, not a consensus collapse. That distinction matters.

The correct tactical posture is to separate the business from the stock.

The business still looks elite. The stock is being asked to justify how elite.

Eli Lilly’s roughly 6% decline was not driven by a single catastrophic headline.

It was the market compressing a premium multiple in response to a more complicated obesity narrative: real pricing pressure, intensifying oral-drug competition, side-effect scrutiny around orforglipron, and the simple fact that a stock of this size and valuation leaves little room for strategic slippage.

That does not mean the Lilly thesis is broken.

It means the stock is being forced to trade on the next phase of the story, not the last one. The last phase was about surging injectable demand and obvious category leadership. The next phase is about whether Lilly can extend that leadership into a broader, cheaper, more competitive oral market without giving up too much on price or tolerability. That is a harder question, and today’s tape reflected it.

_{Editorial Disclaimer}

_{This commentary is for informational and educational purposes only and does not constitute investment advice. All market strategies involve risk, and past performance is not indicative of future results. Readers should conduct their own analysis or consult a licensed financial professional before making investment decisions.}